Feasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography.

2.50
Hdl Handle:
http://hdl.handle.net/10541/92011
Title:
Feasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography.
Authors:
Moore, James V; Waller, Michael L; Zhao, Sha; Dodd, Nicholas J F; Acton, P D; Jeavons, A P; Hastings, D L
Abstract:
One early effect of the treatment of tumours by the new modality photodynamic therapy (PDT) is a reduction in tumour glucose levels. We have employed the widely used positron-emitting glucose analogue flurorine-18 fluoro-2-deoxy-D-glucose ([18F]-FDG), to determine whether, in principle, PDT-induced injury might be delineated non-invasively and quantitatively by positron emission tomography (PET). The scanner was of the high-density avalanche-chamber (HIDAC) type with a resolution of 2.6 mm. Subcutaneous T50/80 mouse mammary tumours, sensitised by haematoporphyrin ester, were illuminated by graded doses of interstitial 630 nm light. Thirty hours later, any remaining viable tumour was detected (a) by region-of-interest analysis of the PET images and (b) by gamma counting the excised tumour. PET measurements of % uptake of [18F]-FDG into tumour correlated closely with ex vivo gamma counting (slope=0.976, r2=0. 995), validating the in situ method. Uptake into untreated, control tumours was 3.8%+/-1.1% of the injected activity. Uptake of [18F]-FDG into treated tumours decreased by 0.7% for every 100 mm3 reduction in remaining viable histological volume. Outcome was further compared with that measured by (a) T2-weighted proton imaging on a 4.7-T magnetic resonance imaging (MRI) system and (b) histological analysis of subsequently sectioned tumours. PET using [18F]-FDG described the absolute volume of surviving tumour histological mass to the same degree as high-resolution MRI. The conclusion of these initial studies is that PET with [18F]-FDG, although non-specific, quantitatively described at early times the extent of tumour destruction by PDT.
Affiliation:
Paterson Institute for Cancer Research, Christie Hospital (NHS) Trust, Manchester, UK.
Citation:
Feasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography. 1998, 25 (9):1248-54 Eur J Nucl Med
Journal:
European Journal of Nuclear Medicine
Issue Date:
Sep-1998
URI:
http://hdl.handle.net/10541/92011
DOI:
10.1007/s002590050292
PubMed ID:
9724373
Type:
Article
Language:
en
ISSN:
0340-6997
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorMoore, James Ven
dc.contributor.authorWaller, Michael Len
dc.contributor.authorZhao, Shaen
dc.contributor.authorDodd, Nicholas J Fen
dc.contributor.authorActon, P Den
dc.contributor.authorJeavons, A Pen
dc.contributor.authorHastings, D Len
dc.date.accessioned2010-02-12T16:01:43Z-
dc.date.available2010-02-12T16:01:43Z-
dc.date.issued1998-09-
dc.identifier.citationFeasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography. 1998, 25 (9):1248-54 Eur J Nucl Meden
dc.identifier.issn0340-6997-
dc.identifier.pmid9724373-
dc.identifier.doi10.1007/s002590050292-
dc.identifier.urihttp://hdl.handle.net/10541/92011-
dc.description.abstractOne early effect of the treatment of tumours by the new modality photodynamic therapy (PDT) is a reduction in tumour glucose levels. We have employed the widely used positron-emitting glucose analogue flurorine-18 fluoro-2-deoxy-D-glucose ([18F]-FDG), to determine whether, in principle, PDT-induced injury might be delineated non-invasively and quantitatively by positron emission tomography (PET). The scanner was of the high-density avalanche-chamber (HIDAC) type with a resolution of 2.6 mm. Subcutaneous T50/80 mouse mammary tumours, sensitised by haematoporphyrin ester, were illuminated by graded doses of interstitial 630 nm light. Thirty hours later, any remaining viable tumour was detected (a) by region-of-interest analysis of the PET images and (b) by gamma counting the excised tumour. PET measurements of % uptake of [18F]-FDG into tumour correlated closely with ex vivo gamma counting (slope=0.976, r2=0. 995), validating the in situ method. Uptake into untreated, control tumours was 3.8%+/-1.1% of the injected activity. Uptake of [18F]-FDG into treated tumours decreased by 0.7% for every 100 mm3 reduction in remaining viable histological volume. Outcome was further compared with that measured by (a) T2-weighted proton imaging on a 4.7-T magnetic resonance imaging (MRI) system and (b) histological analysis of subsequently sectioned tumours. PET using [18F]-FDG described the absolute volume of surviving tumour histological mass to the same degree as high-resolution MRI. The conclusion of these initial studies is that PET with [18F]-FDG, although non-specific, quantitatively described at early times the extent of tumour destruction by PDT.en
dc.language.isoenen
dc.subjectHaematoporphyrin Photoradiationen
dc.subject.meshAnimals-
dc.subject.meshFeasibility Studies-
dc.subject.meshFemale-
dc.subject.meshFluorine Radioisotopes-
dc.subject.meshFluorodeoxyglucose F18-
dc.subject.meshHematoporphyrin Photoradiation-
dc.subject.meshMagnetic Resonance Imaging-
dc.subject.meshMammary Neoplasms, Experimental-
dc.subject.meshMice-
dc.subject.meshMice, Nude-
dc.subject.meshRadiopharmaceuticals-
dc.subject.meshTomography, Emission-Computed-
dc.titleFeasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Christie Hospital (NHS) Trust, Manchester, UK.en
dc.identifier.journalEuropean Journal of Nuclear Medicineen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.